National Cancer Institute; Notice of Meeting, 38910-38911 [2024-10060]
Download as PDF
38910
Federal Register / Vol. 89, No. 90 / Wednesday, May 8, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group; Diabetes,
Endocrinology and Metabolic Diseases B
Study Section.
Date: June 5–7, 2024.
Time: 5:30 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015 (In-Person Meeting).
Contact Person: Charlene J. Repique, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7347, 6707 Democracy Boulevard
Bethesda, MD 20892–5452, (301) 594–7791,
charlene.repique@nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group; Fellowships in
Digestive Diseases and Nutrition.
Date: June 13–14, 2024.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike Rockville, MD 20852, (InPerson Meeting).
Contact Person: Jian Yang, Ph.D., Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
7011, 6707 Democracy Blvd., Bethesda, MD
20892–5452, (301) 594–7799, yangj@
extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group; Kidney, Urologic and
Hematologic Diseases D Study Section.
Date: June 26–27, 2024.
Time: 8:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015 (In-Person Meeting).
Contact Person: Jason D. Hoffert, Ph.D.,
Scientific Review Officer, Review Branch,
VerDate Sep<11>2014
17:03 May 07, 2024
Jkt 262001
Division of Extramural Activities, NIDDK,
National Institutes of Health, Room 7343,
6707 Democracy Boulevard, Bethesda, MD
20892, 301–496–9010, hoffertj@
niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: May 2, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10017 Filed 5–7–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer
Advisory Board and NCI Board of
Scientific Advisors.
This will be a hybrid meeting held inperson and virtually and will be open to
the public as indicated below.
Individuals who plan to attend inperson or view the virtual meeting and
need special assistance or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
can be accessed from the NIH Videocast
at the following link: https://
videocast.nih.gov/.
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Date: June 11, 2024.
Open: 6:00 p.m. to 9:00 p.m.
Agenda: National Cancer Advisory Board
Subcommittee Meetings.
Place: Gaithersburg Marriott
Washingtonian Center, Room—TBD, 9751
Washington Boulevard, Gaithersburg, MD
20878 (In Person Meeting).
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Contact Person: Paulette S. Gray, Ph.D.,
Director Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Name of Committee: National Cancer
Advisory Board and NCI Board of Scientific
Advisors.
Date: June 12, 2024.
Open: 9:00 a.m. to 3:50 p.m.
Agenda: Joint meeting of the National
Cancer Advisory Board and NCI Board of
Scientific Advisors, NCI Director’s Report
and Presentations.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Room
TE406 & 408, Rockville, MD 20850 (In Person
and Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Director Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Name of Committee: National Cancer
Advisory Board.
Date: June 12, 2024.
Closed: 3:50 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Room
TE406 & 408, Rockville, MD 20850 (In Person
and Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Director Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Name of Committee: National Cancer
Advisory Board and NCI Board of Scientific
Advisors
Date: June 13, 2024.
Open: 9:00 a.m. to 12:00 p.m.
Agenda: Joint meeting of the National
Cancer Advisory Board and NCI Board of
Scientific Advisors, NCI Board of Scientific
Advisors Concepts Review and Presentations.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Room
TE406 & 408, Rockville, MD 20850 (In Person
and Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Director Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NCI-Shady Grove campus. All
visitors will be asked to show one form of
identification (for example, a government-
E:\FR\FM\08MYN1.SGM
08MYN1
Federal Register / Vol. 89, No. 90 / Wednesday, May 8, 2024 / Notices
issued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: NCAB: https://
deainfo.nci.nih.gov/advisory/ncab/ncab.htm,
BSA: https://deainfo.nci.nih.gov/advisory/
bsa/bsa.htm, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: May 3, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10060 Filed 5–7–24; 8:45 am]
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Bita Nakhai, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, 7201
Wisconsin Avenue, Gateway Bldg. Suite
2C212, Bethesda, MD 20892, 301–402–7701,
nakhaib@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: May 2, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–10020 Filed 5–7–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
BILLING CODE 4140–01–P
Federal Emergency Management
Agency
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket ID FEMA–2023–0027]
National Institutes of Health
Programmatic/Class Floodplain
Review Procedures for Specific
Preparedness Grant Projects
National Institute on Aging; Notice of
Closed Meetings
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; AD and
ADRD Infrastructure.
Date: June 17, 2024.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Nijaguna Prasad, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, 7201
Wisconsin Avenue, Gateway Bldg. Suite
2W200, Bethesda, MD 20892, (301) 496–
9667, prasadnb@nia.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Aging
Courses.
Date: July 3, 2024.
VerDate Sep<11>2014
17:03 May 07, 2024
Jkt 262001
Federal Emergency
Management Agency, Department of
Homeland Security.
ACTION: Final notice.
AGENCY:
On October 4, 2023, FEMA
published a notice requesting public
comment on its determination that a
programmatic/class review is
appropriate for six categories of
activities, in specific grant programs
that do not have an adverse impact,
individually or cumulatively, on
floodplain values placing property and
persons at risk. FEMA received no
comments and is now publishing final
notice of its determination in
compliance with Federal regulations.
FOR FURTHER INFORMATION CONTACT:
Frederick Holycross, Coordinator, Grant
Programs Directorate, Environmental
Planning and Historic Preservation,
FEMA, frederick.holycross@
fema.dhs.gov, or 202–812–4938.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
FEMA’s floodplain management
regulations are found at 44 CFR part 9.
Part 9 sets forth the policy, procedure,
and responsibilities to implement and
enforce Executive Order 11988,
Floodplain Management.1 Part 9 sets
1 ‘‘This regulation sets forth the policy,
procedure, and responsibilities to implement and
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
38911
forth an eight-step process which FEMA
must follow when taking actions in
floodplains 2 which have the potential
to affect floodplains or their occupants,
or which are subject to potential harm
by location in floodplains.3 FEMA
completes the eight-step process for
each action it is taking in a floodplain
as part of the comprehensive
environmental and historic preservation
(EHP) compliance reviews that are
required for all projects funded under
its disaster and non-disaster grant
programs.4
For such actions, FEMA is required to
take the following steps: (1) determine
whether the proposed action is located
in the 100-year floodplain (500-year
floodplain for critical actions), and
whether it has the potential to affect or
be affected by the floodplain; 5 (2) notify
the public at the earliest possible time
of the intent to carry out an action in a
floodplain, and involve the affected and
interested public in the decision-making
process; (3) identify and evaluate
practicable alternatives to locating the
proposed action in a floodplain
(including alternative sites, actions and
the ‘‘no action’’ option); (4) identify the
potential direct and indirect impacts
associated with the occupancy or
modification of floodplains and the
potential direct and indirect support of
floodplain development that could
result from the proposed action; (5)
minimize the potential adverse impacts
and support to or within floodplains to
be identified under Step 4, restore and
preserve the natural and beneficial
values served by floodplains; (6)
reevaluate the proposed action to
determine first, if it is still practicable
in light of its exposure to flood hazards,
the extent to which it will aggravate the
hazards to others, and its potential to
disrupt floodplain values and second, if
alternatives preliminarily rejected at
Step 3 are practicable in light of the
information gained in Steps 4 and 5; (7)
prepare and provide the public with a
finding and public explanation of any
final decision that the floodplain is the
only practicable alternative; and (8)
enforce Executive Order 11988, Floodplain
Management, and Executive Order 11990,
Protection of Wetlands.’’ 44 CFR 9.1.
2 The 8-step process set forth in 44 CFR part 9
also governs agency actions that take place in
wetlands.
3 44 CFR 9.5(a)(1).
4 See generally FEMA’s website at Environmental
Planning and Historic Preservation for a description
of the EHP process and the applicable regulations,
directives, and legal mandates which govern it.
(Last accessed on April 12, 2024.)
5 Any project considered for streamlined process
will also be subject to a determination of whether
the proposed action is located in a wetland and/or
floodplain.
E:\FR\FM\08MYN1.SGM
08MYN1
Agencies
[Federal Register Volume 89, Number 90 (Wednesday, May 8, 2024)]
[Notices]
[Pages 38910-38911]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-10060]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Cancer
Advisory Board and NCI Board of Scientific Advisors.
This will be a hybrid meeting held in-person and virtually and will
be open to the public as indicated below. Individuals who plan to
attend in-person or view the virtual meeting and need special
assistance or other reasonable accommodations, should notify the
Contact Person listed below in advance of the meeting. The meeting can
be accessed from the NIH Videocast at the following link: https://videocast.nih.gov/.
A portion of the National Cancer Advisory Board meeting will be
closed to the public in accordance with the provisions set forth in
sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The
grant applications and the discussions could disclose confidential
trade secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board.
Date: June 11, 2024.
Open: 6:00 p.m. to 9:00 p.m.
Agenda: National Cancer Advisory Board Subcommittee Meetings.
Place: Gaithersburg Marriott Washingtonian Center, Room--TBD,
9751 Washington Boulevard, Gaithersburg, MD 20878 (In Person
Meeting).
Contact Person: Paulette S. Gray, Ph.D., Director Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, 7th Floor,
Room 7W444, Bethesda, MD 20892, 240-276-6340, [email protected].
Name of Committee: National Cancer Advisory Board and NCI Board
of Scientific Advisors.
Date: June 12, 2024.
Open: 9:00 a.m. to 3:50 p.m.
Agenda: Joint meeting of the National Cancer Advisory Board and
NCI Board of Scientific Advisors, NCI Director's Report and
Presentations.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Room TE406 & 408, Rockville, MD 20850 (In Person and
Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D., Director Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, 7th Floor,
Room 7W444, Bethesda, MD 20892, 240-276-6340, [email protected].
Name of Committee: National Cancer Advisory Board.
Date: June 12, 2024.
Closed: 3:50 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Room TE406 & 408, Rockville, MD 20850 (In Person and
Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D., Director Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, 7th Floor,
Room 7W444, Bethesda, MD 20892, 240-276-6340, [email protected].
Name of Committee: National Cancer Advisory Board and NCI Board
of Scientific Advisors
Date: June 13, 2024.
Open: 9:00 a.m. to 12:00 p.m.
Agenda: Joint meeting of the National Cancer Advisory Board and
NCI Board of Scientific Advisors, NCI Board of Scientific Advisors
Concepts Review and Presentations.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Room TE406 & 408, Rockville, MD 20850 (In Person and
Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D., Director Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, 7th Floor,
Room 7W444, Bethesda, MD 20892, 240-276-6340, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NCI-Shady Grove campus. All
visitors will be asked to show one form of identification (for
example, a government-
[[Page 38911]]
issued photo ID, driver's license, or passport) and to state the
purpose of their visit.
Information is also available on the Institute's/Center's home
page: NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm, BSA:
https://deainfo.nci.nih.gov/advisory/bsa/bsa.htm, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: May 3, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-10060 Filed 5-7-24; 8:45 am]
BILLING CODE 4140-01-P